Citation only
via OpenAlex
EFFECTS OF TRANSIENT MID-LIFE RAPAMYCIN TREATMENT ON LIFESPAN AND HEALTHSPAN
Authors not listed
The Gerontologist · 2016
Abstract
EFFECTS OF TRANSIENT MID-LIFE mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">RAPAMYCIN(definition) TREATMENT ON LIFESPAN AND HEALTHSPAN(definition) M. Kaeberlein, Pathology, University of Washington, Seattle, Washington The FDA approved drug rapamycin has been shown to increase lifespan and healthspan in laboratory model organisms such as yeast, worms, flies and mice. In mice, treatment with rapamycin beginning at middle-age is sufficient to increase lifespan and improve measures of both cardiac and immune function. Nevertheless, important questions exist regarding the translational potential of rapamycin and other mTOR inhibitors for human aging, and the optimal dose, duration, and mechanisms of action remain to be determined. Here I will report on recent studies examining the effects of short-term treatment with rapamycin in middle-aged mice and dogs. We find that transient treatment with rapamycin is sufficient to increase life expectancy by more than 50% and improve measures of healthspan in middle-aged mice. At the highest dose tested, this transient treatment is also associated with a remodelling of the gut microbiome, along with a dramatic shift in the cancer spectrum in female mice. In dogs, we have defined a dose of rapamycin that is well tolerated, and initial results are consistent with improvements in age-associated cardiac function similar to those observed in rapamycin-treated mice. These data suggest that a transient treatment with rapamycin may yield robust health benefits in mice, dogs, and perhaps humans.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/geront/gnw162.2793
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Anonymous. (2016). EFFECTS OF TRANSIENT MID-LIFE RAPAMYCIN TREATMENT ON LIFESPAN AND HEALTHSPAN. <em>The Gerontologist</em>. https://doi.org/10.1093/geront/gnw162.2793
Vancouver
Anonymous. EFFECTS OF TRANSIENT MID-LIFE RAPAMYCIN TREATMENT ON LIFESPAN AND HEALTHSPAN. The Gerontologist. 2016. doi:10.1093/geront/gnw162.2793.
BibTeX
@article{anon2016EFFECT,
title = {EFFECTS OF TRANSIENT MID-LIFE RAPAMYCIN TREATMENT ON LIFESPAN AND HEALTHSPAN},
author = {Anonymous},
journal = {The Gerontologist},
year = {2016},
doi = {10.1093/geront/gnw162.2793},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
eLife 2016
Open access · CC-BY
Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice
bioRxiv (Cold Spring Harbor Laboratory) 2026
Preprint · CC-BY
Strong inhibition of insulin/IGF-1 signaling in early-mid adulthood compresses morbidity, but in later life accelerates aging
2026
Preprint
Strong inhibition of insulin/IGF-1 signaling in early-mid adulthood compresses morbidity, but in later life accelerates aging
Aging Cell 2017
Open access · CC-BY
Movement decline across lifespan of Caenorhabditis elegans mutants in the insulin/insulin‐like signaling pathway
International Journal of Molecular Sciences 2021
Open access · CC-BY
The Role of mTOR Signaling as a Therapeutic Target in Cancer
EMBO Reports 2022
Open access · CC-BY